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Lipid Rescue for Cardiotoxicity
Secondary to Anesthetic Medications
By Brianne Dunn, PharmD
PGY1 Pharmacy Resident
Local anesthesia is widely used
throughout MUSC. While generally safe, local anesthesia (LA)
can be toxic if used in inappropriate doses or routes. Even
when properly administered, patients may experience unintended reactions to LA.1-5 Inadvertent intravascular injection is
the most common cause of LA
toxicity even when administered
within the recommended dosage
range.1,5
LA involves the injection of an
local anesthetic agent into the
skin and subcutaneous tissue,
anesthetizing the skin surrounding the injection site.1,2 These
agents can be classified into 2
groups, the esters and the amides. The esters have shortacting properties and, therefore,
are used for brief surgical cases.
Amides are longer-acting in
terms of block efficacy.3 Onset
of action, potency, and duration
of action are determined by the
pharmacokinetic and pharmacodynamic properties of each specific agent, such as pKa, lipid
solubility, protein binding, tissue
pH and vasodilatory effects.1
Agents with greater lipid solubility generally demonstrate a

greater potency while those with
high protein binding show increased duration of action.3 Toxicity is related to the structure,
mechanism of action, and pharmacokinetic profile of LA agents.2 A
summary of the properties of LA
agents is included in Table 1.
Systemic toxicity related to a LA
overdose was first described in a
1928 report of 40 fatalities.7 Peripheral nerve blocks carry the
highest rates of systemic toxicity,
which is estimated to occur in
0.1% of procedures.5 Toxicity
from epidural administration is
less common with an incidence of
0.04%.5 Changes in practice and
increased attention to LA safety
may help lower rates of toxicity.
Safe practices include administering LA agents in divided doses,
performing aspiration tests, following recommendations for dose
limitations and administering test
doses of epinephrine to detect inadvertent intravascular administration.2 The maximum recommended doses of LA are listed in
Table 1.
The toxicity of LA agents can be
classified by manifestations at the
local or systemic level. Local ad-
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Table 1. Properties of Individual Local AnesthetLocal
Anesthetic
Esters

Time to
Onset

Duration
(min)

Half-life
(hr)

Max Dose
(mg)

Max Dose
(mg/kg)

Min Toxic Dose
(mg/kg)

Chloroprocaine
(Nesacaine®)

Short

Short
(15-30)

<30 sec

800

11

22.8

Procaine
(Novocain®)

Long

Short
(15-60)

N/A

350-600

7

19.2

Tetracaine
(Pontocaine®)

Long

Long

N/A

100

1.5

2.5

Bupivacaine
(Marcaine®)

Medium

Long
(120-360)

2.7

150-175

1-2.5

1.6

Lidocaine
(Xylocaine®)

Short

Medium
(30-60)

1.6

300

4-5

6.4

Mepivacaine
(Polocaine®,
Carbocaine®)

Short

Medium
(45-90)

1.9

400

7

9.8

Prilocaine
(Citanest®)

Short

Medium
(30-90)

1.5

500-600

5-8

N/A

Ropivacaine
(Naropin®)

Medium

Long
(120-360)

1.8

200

5

N/A

Amides

verse effects include neurovascular manifestations such as prolonged anesthesia and paresthesias.1 Systemic toxicity of anesthetics involves the central nervous system (CNS), cardiovascular
system, and immune system.1-5
Allergic reactions are more common with ester LA agents as compared to amides, and may range
from minor dermatitis to anaphylaxis.2 Some anesthetics, particularly benzocaine, are associated
with hematologic effects such as
methemoglobinemia.1,6 The toxicity of anesthetics may be potentiated in patients with renal or hepatic dysfunction, respiratory acidosis, preexisting heart block, or
other heart conditions.1
After the use of LA agents, a patient should be closely observed
for signs and symptoms of possible toxicity.1 Frequent monitoring
of blood pressure, heart rate and

rhythm, and oxygen saturation
may provide early warning signs
of systemic toxicity. Table 2
provides a summary of some of
the common signs and symptoms of toxicity.
At low drug concentrations,
CNS effects may begin as a ringing in the ears. As blood levels

icity are generally self-limiting
and precede signs of cardiac toxicity. Therefore, seizures may alert
healthcare providers of the possibility of progression to CNS depression or impending cardiovascular collapse.2
The cardiovascular toxicity of LA
medications is generally the most

Table 2. Local Anesthetic Toxicity2-6
Early Signs
Moderate Toxicity

Severe Toxicity

Agitation

CNS excitation

Hypotension

Lightheadedness

Cardiac arrhythmias

Bradycardia

Altered mental status

Contractile depression

Ventricular arrhythmias

Visual changes

Conduction blockade

Cardiovascular collapse

Slurred speech

Seizures

Mild hypertension

Coma

Tachycardia

increase further, dizziness, altered mental status, seizure activity, and coma may ensue.3,5
Seizures that result from LA tox-

ominous presentation of toxicity.5
When present in excess, the actions of LA agents on sodium
channels contribute to cardiac tox-
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icity and may also be affected by
secondary effects of LA agents on
calcium and potassium channels,
and the inhibition of cyclic adenosine monophosphate production.2,5
Cardiotoxic effects may be enhanced by pre-existing hypoxia or
acidosis secondary to seizure activity.3 These effects are first observed as hypotension and bradycardia, but rapidly progresses to
arrhythmias and cardiovascular
collapse.5 The long-acting agents,
such as bupivacaine, are more
strongly associated with cardiovascular toxicity compared with
the short-acting agents.2 The most
concerning aspect of LA-induced
cardiovascular collapse is that is it
is generally refractory to traditional advanced cardiac life support (ACLS) interventions. Until
recently, cardiopulmonary bypass
was the only method shown effective in treating refractory cardiac
arrest from local anesthetic overdose.7
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essential fatty acid deficiency.8,9
This product is comprised of
20% soybean oil, 1.2% egg yolk
phospholipids, 2.25% glycerin,
and water for injection. 5,9 The
major fatty acid components are
linoleic, oleic, palmitic, linolenic, and stearic acid.5,9

A new potential antidote for LA
toxicity, intravenous lipid emulsion (IVLE), has been gaining increased attention in the literature.
Both animal studies and human
case reports have described successful resuscitation with IVLE in
the face of presumed or documented LA toxicity.2

Despite the increasing literature
on the use of IVLE in LA toxicity, its mechanism remains unknown.2-5 One theory is that
IVLE serves as a “lipid sink,”
providing a large lipid phase in
the serum that is able to extract
LA from the plasma or tissues.2-5
The rapid binding of excess LA
with lipid infusion reduces the
plasma drug concentration and
allows for restoration of hemodynamic stability.3 Another theory is that IVLE has metabolic
effects by inhibiting mitochondrial metabolism of lipids, reducing tissue acidosis and decreasing carbon dioxide production during times of myocardial
ischemia. Also, IVLE may work
to saturate the LA-impaired fatty
acid delivery to the mitochondria, enabling further energy
production.2,5 An additional theory is that the fatty acids found
in IVLE activate calcium and
potassium channels, which have
been associated with LAinduced cardiotoxicity.2

Intralipid 20% is a fat emulsion
that is approved by the US Food
and Drug Administration (FDA)
for use as a source of calories and
essential fatty acids for patients
who require parenteral nutrition
for extended periods of time. Additionally, it is indicated as a
source of essential fatty acids for
the prevention and treatment of

Based on investigational studies
in rats and dogs in the late
1990s, a trial of IVLE in humans
was warranted.10,11 There have
been 9 successful case reports
documented in humans with the
use of lipid infusion in resuscitation efforts involving suspected
or documented LA toxicity to
date (Table 3).12-20

IVLE as rescue therapy following
LA induced cardiac arrest unresponsive to conventional resuscitation is an off-label use of this
treatment.8,9 Formal dose-ranging
studies have not been performed
in humans and dosing information
can only be extrapolated from human case reports.12-20 While the
human case reports all used IVLE
20%, the amount infused varied
with each case.2 The various dosing regimens in the published case
reports are summarized in Table
3. Although there are no formal
guidelines in the US, Weinberg
and Picard have developed a web
site that may serve as a reference
site
for
lipid
rescue
11
(http://lipidrescue.org). The authors of this web site propose a
dosing regimen of IVLE 20% as a
bolus of 1.5 mL/kg over 1 minute,
followed by a continuous infusion
of 0.25 mL/kg/min for 30 to 60
minutes. In the setting of hypotension, the infusion may be
increased to 0.5 mL/kg/min. The
patient may be rebolused 1 or 2
times every 3 to 5 minutes if no
evidence of clinical improvement.
Weinberg suggests that cumulative doses greater than 8 mL/kg
are unlikely to be effective. IVLE
is recommended in patients who
do not respond to standard resuscitation efforts. Chest compressions still need to be performed to
allow circulation of the IVLE
throughout the body.11
In 2007, the Association of Anaesthetists of Great Britain & Ireland developed guidelines for the
management of severe LA toxicity. The treatment algorithm of
cardiac arrest with lipid emulsion
is similar to that of Weinberg and
colleagues, with the exception of
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the bolus dose.21 However, there are discrepancies between what has been suggested by these researchers and
what has actually been done in the published case reports.11-21 Therefore, the ideal dose and dosing regimen of
IVLE in LA toxicity remains to be determined.
Table 3. Summary of Human Case Reports11-21
Reference

Local
Anesthetic

Adverse
Reaction

Lipid
Formulation

Lipid Rescue11

N/A

N/A

Intralipid 20%

Association of
Anaesthetists of
Great Britain
and Ireland21

N/A

N/A

Intralipid 20%

Rosenblatt12

Bupivacaine
Mepivacaine

Litz13

Ropivacaine

Foxall14

Levobupivacaine

Spence15

Bupivacaine

Seizure
Asystole
Seizure
Asystole
Seizure
EKG changes
Hypertension
Tachycardia
Loss of consciousness

Intralipid 20%
Intralipid 20%

Bolus
Dose
1 mL/kg x 3
doses
1.5 mL/kg x
3 doses
1.2 mL/kg
single dose
2 mL/kg single dose

Time Bolus
Given

Infusion
Rate

N/A

0.25 mL/kg/min

N/A

0.25 mL/kg/min

20 min

0.5 mL/kg/min

10 min

0.2 mL/kg/min

Intralipid 20%

1.2 mL/kg

4 min

Not given

Intralipid 20%

0.58 mL/kg x
2 doses

2 min

400 mL as infusion (rate unknown)

Bupivacaine

Seizure
Ventricular
tachycardia

Intralipid 20%

100 mL +
400 mL
(weight unknown)

5 min

Not given

Warren17

Bupivacaine
Mepivacaine

Pulseless

Liposyn III 20%

unknown

10 min

0.1 mL/kg/min

Smith18

Bupivacaine

Seizure
Asystole

Intralipid 20%

3 mL/kg

1 min

0.2 mL/kg/min

Immediate at
onset of
symptoms

0.25 mL/kg/min

Immediate at
onset of
symptoms

Not given

McCutchen

16

Litz19

Mepivacaine
Prilocaine

Supraventricular
extrasystoles

Intralipid 20%

1 mL/kg x
2 doses
(2nd dose
given 3 min
after 1st dose)

Ludot20

Ropivacaine
Lidocaine

Ventricular
arrhythmias

Medialipid 20%

3 mL/kg

IVLE has a benign safety profile based on its frequent and longstanding use in parenteral nutrition. Adverse
reactions are minimal, with potential complications being infectious complications, thrombophlebitis during
peripheral intravenous administration and allergic reactions.4,5,8,22 More delayed reactions occur when fat
emulsions are given in excessively high doses, leading to fat accumulation. Manifestations of fat overload can
include hyperlipidemia, hepatotoxicity, jaundice, seizures, thrombocytopenia and fat embolism.5,8,9 The main
safety concern for IVLE use in the acute setting is allergic reactions.8,22 Medications formulated in lipid emulsions, like propofol, should not be considered options.1,2,6 To date, there have been no reports of IVLE being
associated with adverse side effects when used for this indication.12-20
In conclusion, the available cases demonstrate that LA toxicity occurs as a result of different regional techniques and with a variety of agents.12-20 Lipid emulsion has been successful in the reversal of LA cardiac toxicity, not just bupivacaine-induced toxicity.22 Although doses of LA used were within recommended dosing
guidelines and steps were taken to minimize the risk of intravascular administration, toxicity still occurred.
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The clinical presentation of the toxic reactions and the timing of their onset varied, thus emphasizing the diversity of the clinical circumstances in which LA toxicity may occur and in which lipid emulsion therapy may
show its benefit.10 Warren et al and Ludot et al demonstrated that the beneficial effect occurs irrespective of
the brand of lipid emulsion.17,20 To date, there have been no case reports of lipid rescue failing; however, there
have been only a small number of published case reports over the past three years.12-20 Additional advantages
of IVLE include low cost and accessibility.5
There remain many details unknown despite the documented successes in the case reports. Guidelines have
yet to be published in the US and the literature supporting IVLE safety and efficacy is still lacking. It is also
unclear how resuscitation with fat emulsion will affect other lipophilic drugs used during advanced cardiac life
support (ACLS), such as amiodarone.5 The most appropriate timing of initiation is still unknown as well as
the optimal and maximal doses to be given. From the available literature, the appropriate rate of administration and duration of therapy cannot be established, but the beneficial trend of using early therapy is evident.1121
Although the adverse effects of this therapy are not known, for a patient in the desperate circumstance of
LA toxicity who is receiving supportive care, conventional treatment and resuscitation efforts, lipid emulsion
therapy seems to be a viable and effective consideration.5,10 References available upon request

New Vancomycin Monitoring Protocol
The Anti-infective Subcommittee recently approved a protocol for vancomycin dosing recommendations,
monitoring parameters, and laboratory monitoring in light of the recently published recommendations and
guidelines from the Infectious Diseases Society of America1,2. In addition, the microbiology and clinical laboratories will also change the reporting of methicillin-resistant Staphylococcus aureus (MRSA) isolates obtained from various cultured specimens and the reporting of range values for vancomycin levels. The following are a summary of the recommendations:
▪ MRSA vancomycin minimum inhibitory concentrations (MICs) will be released automatically by the microbiology

▪
▪
▪
▪
▪

laboratory on the following specimen types:
− Blood cultures
− Respiratory cultures including sputum, endotracheal aspirates, bronchoalveolar lavage (BAL), mini-BAL, transbronchial lung biopsy, and lung biopsy
− Cerebrospinal fluid cultures
The microbiology laboratory will enter the following disclaimer when a vancomycin MIC result is released: Vancomycin efficacy may be compromised with MRSA isolates with MICs of 2 micrograms/mL or greater. Please contact
Infectious Diseases or the Antimicrobial Stewardship Team for guidance in dosing or therapeutic alternatives.
Alternative antibiotic agents, linezolid and daptomycin, indicated to treat serious MRSA infections will remain under
the restricted antibiotics list and will have the same current approval mechanism to be dispensed by the pharmacy.
The microbiology laboratory will keep the same policies in effect in regards to reporting linezolid and daptomycin
susceptibilities.
The clinical laboratory will change the currently used vancomycin normal range when reporting trough concentrations
to 10 to 20 micrograms/mL. Test results with a value below 10 micrograms/mL will include a comment stating
“Subtherapeutic for MRSA infections”.
It is recommended that a vancomycin loading dose of 25 to 30 mg/kg be administered to critically ill patients.
− Vancomycin infusion times should be adjusted accordingly: approximately 30 minutes for every 500 mg infused.

On October 1st, the microbiology and clinical laboratories will be instituting these changes and they should appear in eCareNet Viewer. The Infectious Diseases consult service as well as the Antimicrobial Stewardship
Team welcome any questions regarding vancomycin MICs, vancomycin dosing, or appropriate therapy for patients with MICs greater than or equal to 2 micrograms/mL.
References available upon request
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FORMULARY UPDATE FOR AUGUST 2009
The Pharmacy and Therapeutics
Committee recently approved the
actions listed below. The formulary
effective date is specified for each
decision is indicated next to the
topic.
ADDITION WITH RESTRICTION
Lacosamide (Vimpat®)
September 15, 2009
Lacosamide, a second generation
anti-epileptic drug (AED) that is
available in an oral and intravenous
(IV) formulation, was added to the
formulary in IV formulation only.
This decision adds a second IV antiepileptic medication to the formulary. IV lacosamide will be restricted to inpatient use only in
those patients who have failed other
therapeutic agents.
200-mg/20-mL vials

Clevidipine (Cleviprex®)
October 15, 2009
Clevidipine is a new dihydropyridine IV calcium channel blocker
that is short-acting and vasoselective. It was added to the formulary
with restrictions to the critical care
areas (ie, ICUs, ORs, ED) and the
Interventional Radiology area (must
be monitored by anesthesia).
Safety concerns with clevidipine
include its contraindications in patients with soy or egg-allergies.
Since the product contains lipids,
the bottle must be changed every 4
hours to avoid microbial growth.
0.5-mg/mL in single-use vials

Doripenem (Doribax®)
October 1, 2009
The primary carbapenem of choice
will be changed to doripenem.
Meropenem will still be available
with prescribing restricted to the
following services: pediatrics, in-

fectious diseases, hematology/
oncology, and in those patients
with suspected or documented
meningitis.
500-mg vials

Esomeprazole (Nexium®)
October 15, 2009
Esomeprazole was determined to
be an effective alternative to other
available proton pump inhibitors
(PPI) and added to the formulary
as the primary PPI for all patient
populations (ie, adult, pediatric,
neonate). Therefore, all other PPIs
(pantoprazole, omeprazole, and
lansoprazole) will be removed
from the formulary.
20- and 40-mg capsules; 10-, 20-, and
40-mg oral suspension packets; 20and 40-mg vials

AUTOMATIC THERAPEUTIC SUBSTITUTION (ATS) PROTOCOL
Doripenem (Doribax®)
October 1, 2009
The Anti-infective Subcommittee
approved the ATS for carbapenem
antibiotics. Orders written for
meropenem will now be converted
to the appropriate dose of
doripenem. A 4-hour infusion
time will be automatically used in
intensive care units for critically
ill patients and in patients with
cystic fibrosis until a pathogen is
identified. The infusion time can
be deescalated to 1 hr if Pseudomonas or Acinetobacter is not
identified or if the physician indicates that he/she wants to reduce
infusion time. Dosing must also
be adjusted in patients with renal
failure per the protocol. The protocol is available on the Formulary and Drug Information Resources Web page.

LINE EXTENSIONS
September 15, 2009
▪ Diltiazem 12-mg/mL
extemporaneous suspension
▪ Esmolol (Brevibloc®)
10-mg/mL vials
− Will only be available in the
Operating Rooms and
Institute of Psychiatry
▪ Morphine suspension 0.4-mg/
mL extemporaneous suspension [pediatric use only]
▪ Japanese encephalitis vaccine
(Ixiaro®) [restricted to the outpatient clinics] (for use in patients 17 years of age or older.)
October 15, 2009
▪ Esmolol (Brevibloc®)
2-g/100-mL IV solution
DELETIONS
September 15, 2009
▪ Oil of wintergreen
▪ Benzethonium/benzocaine
0.1%/20% (Americaine®)
spray/ointment
▪ Rubella virus vaccine
(Meruvax II®) single-dose vial
▪ Measles live virus vaccine
(Attenuvax®) single-dose vial
▪ Cromolyn sodium (Intal®)
800-microgram/puff inhaler
October 15, 2009
▪ Esmolol (Brevibloc®)
1-g/100-mL IV solution
▪ Pantoprazole (Protonix®)
20- and 40-mg tablets; 40-mg
injection; 2-mg/mL extemporaneous suspension
▪ Lansoprazole (Prevacid®) 15and 30-mg capsules; 3-mg/mL
extemporaneous suspension
▪ Omeprazole (Prilosec®)
2-mg/mL extemporaneous
suspension

Visit the Formulary and Drug Information Resources Web page at www.formularyproductions.com/musc.

